Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab vs Vedolizumab in Ulcerative Colitis (LUCENT-ACT)
NCT04469062Phase 3Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of mirikizumab in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Planned start Apr 2021; status: withdrawn.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04469062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469062.